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Purpose: To determine the effects of the vascular endothelial growth factor (VEGF)-A165 delivered using a high capacity
adenoviral vector (HC Ad.VEGF-A) on vascular growth and pathological changes in the rabbit eye. To combine different
detection methods of VEGF-A165 overexpression-induced neovascularization in the rabbit.
Methods: HC Ad.VEGF-A165 was constructed and injected at 5x106  infectious units  (iu)  into the subretinal space of
rabbit  eyes.   Two   and   four  weeks   postinjection,  the   development  of  neovascularization   and   the   expression  of
HC Ad-transduced VEGF-A165 protein were followed up in vivo by  scanning laser ophthalmoscopy, fluorescein and
indocyanine green angiographies and ex vivo by electron microscopy and immunohistochemistry
Results: We observed a choroidal neovascularization (CNV) with leakage in 83% of the rabbit eyes. Our findings present
clear indications that there is a significant effect on the endothelial cells of the choriocapillaris after subretinal transduction
of the retinal pigment epithelium (RPE) with VEGF-A165 vector. The choroidal endothelial cells were activated, adherent
junctions opened, and the fenestration was minimized, while the extracellular matrix localized between the RPE and the
endothelium of the choriocapillaris was enlarged toward the lumen of the vessels, inducing a deep invagination of the
endothelial cells into the vessel lumen. They also proliferated and formed pathological vessels in the subretinal space.
Moreover,there was an increased expression of basic fibroblast growth factor and VEGF-A accompanied by macrophage
stimulation, retinal edema, and photoreceptor loss.
Conclusions: This is the first model of VEGF-induced CNV in the rabbit in which the pathological events following
overexpression of VEGF by RPE cells have been described in detail. Many of the features of our experimental CNV
resemble those observed clinically in patients having wet age-related macular degeneration.
Pathological angiogenesis is a major problem in many
ocular  diseases.  The  most  important  angioproliferative
diseases  in  ocular  tissues  include  diabetic  proliferative
retinopathy,  age-related  macular  degeneration  (AMD)  in
adults,  and  retinopathy  of  prematurity  in  infants.  These
diseases  are  the  most  common  causes  for  blindness  in
developed countries [1]. Choroidal neovascularization (CNV)
is  an  important  component  of  subsequent  vision  loss  in
neovascular AMD [2]. In patients with the exudative or “wet”
form of the disease, choroidal blood vessels grow through
Bruch’s  membrane  into  the  subretinal  space,  followed  by
leakage  and  accumulation  of  serum  or  blood  beneath  the
retinal pigment epithelium (RPE), leading to insult of the
retina and rapid vision loss [3]. Although the molecular basis
of AMD is not well understood, several growth factors have
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been  implicated  in  the  disease  process,  including  basic
fibroblast  growth  factor  (bFGF/FGF-2)  [4],  transforming
growth factor (TGF)-β [5], and vascular endothelial growth
factor (VEGF) [4,6,7]. Several lines of evidence suggest that
VEGF is a major stimulator of CNV in AMD, including an
observed increase of VEGF in the RPE of maculae from
patients with AMD [8], increase of VEGF expression in the
laser model of CNV in monkey [9] and rat [10], and induction
of CNV in ectopically delivered VEGF cDNA to the RPE of
rats [11-13] and nonhuman primates [14]. VEGF is a secreted
peptide  that  has  five  homodimeric  variants  formed  by
alternative splicing: VEGF-A, VEGF-B, VEGF-C, VEGF-D,
and placenta growth factor (PIGF). These differ in their ability
to bind to VEGF receptors that are primarily expressed in
endothelial cells. Of these variants, the 165-amino-acid-long
VEGF-A165 is the most commonly expressed isoform in the
ischemic retina [15]. Because of cumulative evidence for the
involvement  of  VEGF  in  AMD,  several  clinical  trials
targeting the VEGF pathway are under way [16]; however the
precise role of VEGF-A in the pathogenesis of CNV still
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1358remains unclear. High levels of VEGF have been found in
excised CNV, but overexpression of VEGF-A specifically in
RPE  cells  failed  to  induce  CNV  [17].  Moreover,
antiangiogenic roles of VEGF-A have been described [18].
The  lack  of  optimal  therapy  is  partially  due  to  the
unavailability  of  appropriate  large  animal  models  for  the
testing of new treatment options for ocular angioproliferative
diseases.  Existing  animal  models  of  CNV  present  several
problems: they are hard to reproduce, they are inefficient, and
the CNV created is not sustainable. The purpose of this study
was to develop an efficient, reliable model of CNV to facilitate
the study of antiangiogenic and antiproliferative therapies for
ocular diseases in the future. We have developed a new model
for CNV by injection of a high-capacity adenovirus vector
encoding for VEGF-A165 (HC Ad.VEGF) into the subretinal
space of rabbits. Gene transduction with vector expressing
VEGF is a well established model as shown in the past [13].
Human adenoviruses of serotype 5 are the preferred vehicle
for in vitro and in vivo gene transfer because of their low
pathogenicity. For the induction of CNV, a high-capacity
“gutless” adenoviral vector with the expression cassette for
the human VEGF-A165 (hVEGF promoter), based on plasmid
pBLAST was used. This type of vector is devoid of viral
coding  sequences  and  allows  for  long-term  in  vivo  gene
expression in resting cell types [19,20].
Moreover, for the first time we have combined detection
methods  of  VEGF-A165  overexpression-induced
neovascularization in mammals: in vivo by scanning laser
ophthalmoscopy (SLO), fluorescein angiography (FA), and
indocyanine green angiography (ICG) and ex vivo by electron
microscopy  and  immunohistochemistry.  This  has  made  it
possible to elucidate the unsettled question of whether, after
VEGF  overexpression,  vascular  leakages  are  induced  by
pathological fenestration in new or existing vessels, by loss of
endothelial cells, or by opening adherent junctions.
METHODS
Generation of pHC Ad.VEGF-A165, pHC Ad.FK7, and pAd.
empty: The vectors were produced by one of the authors
(S.K.).  To  generate  pHC  Ad.VEGF-A165,  the  expression
cassette for human VEGF-A165 was excised from the plasmid
pBLAST49-hVEGF (Invivogen, San Diego, CA) by PvuI and
SwaI, blunt-ended with T4 polymerase, and subcloned into
the unique SwaI site of pSTK129. Expression of VEGF-A165
in this expression cassette is driven by a hybrid EF1α/HTLV
hybrid promoter and a Simian virus 40 polyadenylation signal.
pSTK129 is a plasmid used for the generation of HC Ad
vectors and contains the left terminus of adenovirus serotype
5 (nucleotides 1 through 440), a 20 kb DNA fragment derived
from  the  human  hypoxanthine-guanine
phosphoribosyltransferase (HPRT) locus HUMHPRTB (gene
map positions 1777–21729), a 6.5 kB human fragment of
C346 (locus HUMDXS455A, cosmid map positions 10205–
16750),  and  the  right  terminus  of adenovirus serotype 5
(nt 35818–35935). The SwaI site used to insert  the  VEGF
expression cassette is located within the HPRT stuffer region.
Generation  of  HC-AdFK7  has  been  serially  amplified  on
293cre66 cells and purified by double CsCl density gradient
centrifugation as described in detail elsewhere [19]. pAd.
empty  vector  is  an  E1-deleted  first-generation  adenovirus
vector without transgene expression cassette.
Generation of high titer purified HC Ad vector stocks: The
plasmids  pHC  Ad.VEGF-A165  and  pHC  A.FK7  were
linearized by PmeI and transduced into 293cre66 cells, which
were subsequently infected with AdLC8cLuc at a multiplicity
of infection (MOI) of 5 [21]. Vectors were serially amplified
with 5 MOI helper virus on 293cre66 cells as described in
Figure 1. In vitro biological activity of high capacity adenovirus
vector encoding for vascular endothelial growth factor A165 (HC
Ad.VEGF-A165)  on  human  umbilical  vascular  endothelial  cells
(HUVEC). A: HUVEC proliferation was measured in response to
supernatants  (SN)  from  ARPE-19  cells  transduced  with  HC
Ad.VEGF-A165 (MOI 20) with vascular endothelial growth factor
(VEGF) protein concentrations as indicated. Blind means without
HUVEC cells and control refers to medium without VEGF and
bFGF. B: HUVEC migration was quantified in response to ARPE-19
cell supernatant (VEGF concentration 162 ng/ml), or commercial
VEGF-A as a positive control. Each experiment was performed in
triplicate and repeated on at least three occasions.
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1359detail  elsewhere  [20]  and  purified  by  discontinous  and
continous  CsCl  density  gradient  centrifugation.  Purified
vectors  were  desalted  by  PD-10  columns  (Amersham,
Freiburg, Germany), and the physical titer, infectious titer,
Figure 2. In vivo examination of the neovascularization development in rabbit eyes. A: After transduction with HC Ad.EGFP FK7, retinal
pigment epithelium cells expressed green fluorescent protein in vivo. Fluorescein angiography (FA; B) or indocyanine green angiography
(ICG; C) did not show blood vessel leakage or abnormality. The injection site is marked by white arrows. D and E: After transduction with
Ad. Empty, which is toxic to the RPE, FA (D) and ICG (E) showed the same image representing a typical window effect. Two weeks (F-I)
and four weeks (J-M) after transduction with high capacity adenoviral vector vascular endothelial growth factorA, FA and ICG were similar.
FA showed hyperfluorescent, spotted, roundish areas in the different eyes (F, H, J, L). Early and late FA (Figure 2F versus Figure 2H) and
ICG (Figure 2G versus Figure 2I) did not show large differences. Early ICG revealed irregularities (black arrow) close to the deeper choroidal
blood vessels (G, K). These irregularities, shown in Figure 4 and Figure 8C, possibly were caused by alterations and leakage of the
choriocapillaris. Late ICG (I, M) stained the environment of the spotted roundish areas visible in (H, L). Probably, ICG filled areas within
the interstitium around cellular proliferations (Figure 4).
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1360and helper virus contamination were determined by a DNA-
based slot-blot assay [22]. The vector preparations used in this
study had a helper virus contamination between 2%–4%.
Cell culture: The ARPE-19 cell line was obtained from the
American Type Culture Collection (Manassas, VA), human
umbilical  vein  endothelial  cells  (HUVEC)  from  Provitro
(Berlin,  Germany).  ARPE-19  cells  were  maintained  in
Dulbecco’s modified Eagle’s medium (DMEM) with 10%
fetal bovine serum. HUVEC cell medium was supplemented
with 22.50 ng/ml of heparin and 5 ng/ml of endothelial cell
growth factor.
In vitro detection of VEGF-A: ARPE-19 cells were seeded in
six-well plates at 106 cells/well. HC Ad.VEGF-A165 was added
at a MOI of 20 and left for 48 h. The media were then replaced
and the cells left for an additional seven days. Supernatants
(SN) were then collected, and secreted VEGF-A was detected
by  sandwich  ELISAs  (DuoSet  ELISA,  R&D  Systems,
Minneapolis,  MN).  Supernatants  from  ARPE-19  cells  not
transduced with HC Ad.VEGF-A165 were used as control.
Human umbilical vein endothelial cell proliferation
assay—To  analyze  proliferation,  we  collected  ARPE-19
supernatants. Undiluted supernatants or supernatants diluted
1:10, 1:100, or 1:1000 were added to HUVECs that were
plated  in  24  well  plates  at  5x103  cells/well.  We  used  a
Figure 3. Quantification of fluorescence intensity at the lesion site
after  fluorescein  angiography.  The  Δlight  intensity  is  the  difference
between the mean values from light intensity at the lesion site and
the mean values from light intensity of an area close to the lesion site.
Four weeks postinjection, the Δlight intensity at the lesion site was on
average  six  times  higher  in  eyes  that  were  injected  with  HC
Ad.VEGF-A  compared  to  the  eyes  that  were  injected  with  HC
Ad.FK7 (control). The highest/lowest Δlight intensity at the lesion site is
indicated by the error bars.
commercial  VEGF-A165  (R&D  Systems)  in  increasing
dilutions (from 50 ng/ml to 0.05 ng/ml) as a positive control.
Three days later, proliferation of the endothelial cells was
measured by incubating at 37 °C in WST1 (Roche, Mannheim,
Germany) for 4 h. The test was performed in an endothelial
cell growth medium advanced (Provitro, Berlin, Germany)
without endogenous VEGF and bFGF. The OD was measured
at 450 nm.
Human  umbilical  vein  endothelial  cell  migration
assay—To analyze migration, we incubated 5x104 HUVEC
per insert in Millicell 24 well hanging cell culture insert, PET
8 μm (Millipore, Bedford, MA) in the same medium used for
the proliferation test with or without the ARPE-19 supernatant
(undiluted) for 6 h at 37 °C. As a positive control, we used the
commercial VEGF-A165 (R&D Systems) at the same dilutions
that we used for the proliferation test. Migrated cells were
visualized by the nuclear fluorescence dye 4’,6-diamidino-2-
phenylindole (DAPI; Alexis, Grünberg, Germany) and were
counted in three random fields per insert.
Animals: Adult Chinchilla Bastard rabbits, weighing 2–2.5
kg, were obtained from Charles River, Sulzfeld, Germany.
The ad libitum-fed animals were treated in compliance with
the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research.
Subretinal injections: The rabbits were anesthetized by an
intramuscular injection of 35 mg/kg ketamine hydrochloride
and 5 mg/kg xylazine hydrochloride. Their pupils were dilated
with 0.5% tropicamide and 2.5% phenylephrine eye drops.
The ocular surface was additionally anesthetized with topical
instillation of 0.5% proparacaine hydrochloride eye drops.
Using  an  operating  microscope,  we  made  a  3  mm
paralimbal conjunctival incision in the supranasal quadrant,
and performed a sclerotomy 2 mm posterior to the corneal
limbus. A 30-gauge needle attached to a Hamilton syringe
(Hamilton  Co.,  Reno,  NV)  was  inserted  through  the
sclerotomy  site  into  the  vitreous  cavity.  High-capacity
adenoviral vector encoding VEGF-A165 was injected into the
subretinal space of rabbits at 5x106 infectious units. We chose
to inject the HC Ad.VEGF-A at this optimal dose based on
results from our previous study about the long-term transgene
expression in the RPE after gene transfer with a high-capacity
adenoviral vector [19]. The injection resulted in a locally
restricted subretinal bleb. In the control animals, 20 μl of
either  PBS  or  HC-AdFK7  (5x106  infectious  units)  were
injected into the subretinal space at a similar location. Topical
antibiotic was applied after the injection.
Follow-up  examination:  Follow-up  procedures  included
scanning  laser  ophthalmoscopy  (SLO),  fluorescein
angiography (FA) and indocyanine green angiography (ICG).
We used a Heidelberg Engineering HRA I SLO (Heidelberg
Engineering, Dossenheim, Germany) modified for the use
with  animals  [23].  The  HRA  I  features  the  two  argon
wavelengths (488 nm and 514 nm) in the short wavelength
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Effects of ARPE19-produced VEGF-A     on  the  function of
human umbilical vein endothelial cells:
165range and two infrared diode lasers (795 nm and 830 nm) in
the long wavelength range. The 488 and 795 nm lasers were
used for FA and ICG angiography. Two device settings for
the field of view were used: 20° for fundus overview, and 10°
for detailed view. Light of shorter wavelengths is generally
more strongly attenuated by ocular structures than that of
longer ones; RPE and choroids especially are, in addition to
the photoreceptors, the main absorbing tissues for visible light
due to their melanin content. In pigmented animals, the short-
wavelength lasers provide the highest quality images of the
retina, but cannot penetrate the RPE and choroids. In contrast,
the infrared lasers show less retinal detail but reveal choroidal
structures down to the sclera. Accordingly, FA provides the
most detailed images of retinal capillaries, whereas ICG adds
information about choroidal vessels but shows less retinal
vasculature detail. An important difference between the dyes
is their affinity to (large) plasma proteins. ICG is bound to
such proteins to more than 98%, whereas fluorescein is only
bound to about 60%–80%. As a consequence, ICG diffuses
only very slowly out of the vascular lumen even if vessels are
fenestrated, whereas fluorescein tends to leak rapidly [24].
Prior to examination, the animals were anesthetized as
described in the previous section, and their pupils were dilated
with 0.5% tropicamide and 2.5% phenylephrine eye drops. A
contact  lens  (Geuder,  Heidelberg,  Germany)  was  used  to
avoid dehydration of the cornea. FA and ICG were performed
using an intravenous injection of a mixture of 37.5 mg/kg
bodyweight fluorescein-Na (University Pharmacy, University
of  Tuebingen,  Germany),  and  25  mg/kg  bodyweight  ICG
(ICG-Pulsion,  Pulsion  Medical  Systems  AG,  Munich,
Germany).
SLO, FA, and ICG were performed in all animals at
postoperative weeks two and four, focusing on the injection
site  area.  The  rabbits  were  sacrificed  by  an  intracardial
injection of 5 ml T61 (Intervet, Unterschleissheim, Germany)
immediately  following  ophthalmoscopy.  All  eyes  were
enucleated  and  were  processed  either  for  examination  by
electron microscopy or by immunohistochemistry.
Quantification  of  the  fluorescence  intensities:  For
quantification, images of the fluorescein angiography from six
animals (three for the control HC Ad.FK7 and three for the
HC Ad.VEGF-A) were analyzed with the Openlab software
(Improvision, Tuebingen, Germany). In all animals, the light
intensity at the lesion site and at an area of approximately the
same size near the lesion site, which served as a background
control, was measured. The Maximum value (white) was 255,
and the minimum value (black) was 0. The intensity of the
background control was then subtracted from the intensity of
the  lesion  site  (Δlight intensity).  The  maximum  deviation  of 
Δlight intensity is indicated by bars.
Light and electron microscopy: The eyes were cleaned of
orbital tissue and, after removal of the cornea, they were fixed
overnight at 4 °C in 2% glutaraldehyde in 0.1 M cacodylate
buffer (pH 7.4) containing 100 mM sucrose. After washing
with  cacodylate  buffer,  areas  of  interest  in  flat  mount
preparations were excised and post-fixed with 1% osmium
tetroxide in 0.1 M cacodylate buffer at room temperature for
1  h.  Dehydration  was  then  started  by  a  series  of  10-min
incubations in 30%, 50%, and 70% ethanol. The samples were
stained  with  saturated  uranyl  acetate.  Dehydration  was
continued by incubations in 70%, 80%, 96% ethanol (10 min
each), absolute ethanol (two times for 15 min each), and
propylene oxide (two times for 15 min each). The samples
were  then  embedded  in  Epon  (SPI-Pon™812  Epoxy
Embedding Kit, SPI supplies, West Chester, PA). Semithin
sections were stained with toluidine blue and examined by
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TABLE 1. OVERVIEW OF THE EFFECTS OF HC AD. VEGF-A165 INJECTION, INCLUDING CONTROL EXPERIMENTS, IN RABBIT EYES.
 
Vector
 
N
In vivo observations                              Ex vivo observations
Fluorescein leakage                      Electron
         in SLO                                microscopy
Immunohisto-
   chemistry
HC Ad.VEGF-A 18 15 9 6
PBS 2 0 0 0
HC Ad.FK7 (EGFP) 4 0 0 0
Ad. Empty 4 0 0 0
This table summarizes the experimental procedures employed in this study. The rows indicate the different vectors used
(“Vector”; 20 µl subretinal injection at a titer 5x106 i.u. for each vector) and the columns indicate the number of eyes used (“N”)
as well as in vivo observations of fluorescein leakage in scanning laser ophthalmoscopy (“fluorescein leakage in SLO”), ex vivo
observations at the ultra structural level of neovascularization, endothelial cell proliferation and migration, remodeling of the
extracellular matrix, and cellular infiltration of Bruch’s membrane (“Electron microscopy”) and observations in paraffin sections
of neovascularization, endothelial cell proliferation and migration, and retinal edema (“Immunohistochemistry”).Figure 4. Semithin sections of the eye
shown  in  Figure  2J,K.  A:  The
endothelial  cell  layer  of  the
choriocapillaris  was  irregular,  and
endothelial  cells  protruded  into  the
vessel  lumen  (black  arrowheads).
Evidence  for  this  is  presented  by
electron microscopy (see Figure 5A-C).
The retinal pigment epithelium (RPE)
cell  layer  was  disrupted  (white
arrowheads),  and  endothelial  cells
migrated  and  proliferated  into  the
subretinal  space  or  between  Bruch’s
membrane and RPE (inset). Evidence
that these cells were endothelial cells is
presented  by  immunohistochemistry
(see  Figure  6A).  These  cellular
proliferations were either solid (white
asterisk in A) or loosely packed with
interstitial spaces (black asterisk in B).
The  photoreceptors  have  already
degenerated,  and  retinal  scar  was
closely  connected  to  the  RPE  and
proliferating  cells.  This  was  probably
why fluorescein leakage was restricted
to the spotted roundish areas visible in
Figure  2.  An  immature  capillary
containing an erythrocyte was located
distally to the RPE (B, white arrow). The
melanocytes  of  the  choroids  were
located  below  the  deeper  choroidal
vessels and are not shown. C and D:
After injection of HC Ad. EGFP or PBS,
the RPE, choriocapillaris (arrowheads)
and  deeper  choroidal  vessels  (arrow)
appeared to be normal. The pigmented
layer,  consisting  predominately  of
melanocytes,  is  marked  by  a  black
asterisk.  The  double  arrows  in  A-C
indicate growth of extracellular matrix
and vessel layers of the choroid after
VEGF expression (A, B) compared to
(C).
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1363light  microscopy  (Axioplan2  imaging®,  Zeiss,  Göttingen,
Germany). For electron microscopy the sections were cut
ultrathin,  stained  with  uranyl  acetate  and  lead  citrate  and
observed using an electron microscope (model 902 A; Carl
Zeiss).
Immunohistochemistry:  The  eyes  were  fixed  in  formalin,
embedded  in  paraffin  wax,  cut  to  5  μm  sections,  and
deparaffinized according to standard procedures. The eyes
were first stained with hematoxylin and eosin to locate the
areas of interest. The following antibodies were used for the
detection  of  immunoreactivity,  respectively:  1:500  mouse
monoclonal anti-human VEGF-A (C-1) antibody (sc-7269;
Santa  Cruz  Biotechnology,  Santa  Cruz,  CA),  1:2000
biotinylated  lycopersicon  esculentum  lectin  and  1:2000
fluorescein lycopersicon esculentum (tomato) lectin (Vector
Laboratories,  Burlingame,  CA)  for  endothelial  cells,  1:50
rabbit polyclonal anti-Ki67 antibody (ab833; Biozol, Eching,
Germany)  for  proliferating  cells,  1:2000  sheep  antirabbit
Figure 5. Electron micrographs obtained after transduction with HC
Ad.VEGF-A. A: An invagination of the the endothelium into the
lumen  of  the  choriocapillaris  containing  extracellular  matrix
(asterisk)  is  shown.  This  caused  the  patchy  appearance  of  the
choriocapillaris lumen presented in Figure 4. B: A cell (asterisk) was
located between the endothelium and Bruch’s membrane. Note the
extremely  frayed  or  fragmented  nucleus  of  an  endothelial  cell
(arrow).  C:  An  endothelial  cell  was  spreading  into  Bruch’s
membrane (B) toward the RPE (arrow). The elastic layer of Bruch’s
membrane is labeled by arrowheads. Sites indicating remodeling of
the extracellular matrix surrounding the choriocapillaris are labeled
by asterisks. D: A cell (C) was migrating into Bruch’s membrane
toward the RPE. The elastic layer of Bruch’s membrane is labeled
by arrowheads. Within the pathological capillary, an erythrocyte (E)
was still present. Scale bars in each image: 1 μm.
albumin (Bethyl Laboratories, Montgomery, TX), 1:50 mouse
monoclonal  anti-FGF/anti-FGF-2  (Upstate,  clone  bFM-2,
Lake Placid, NY), and 1:50 mouse monoclonal antirabbit
macrophages  (RAM-11;  MO633;  Dako  Cytomation,
Carpinteria, CA). Stained retinal sections were embedded in
FluorSave (Calbiochem, Darmstadt, Germany) and inspected
using a fluorescent microscope.
In  vivo  detection  of  VEGF-A:  VEGF-A  production  was
analyzed by performing ELISA (human VEGF-A assay kit,
Quantikine; R&D Systems) on vitreous samples two and four
weeks after transduction of RPE cells with HC Ad. VEGF-A
(n=4), with HC Ad. EGFP (n=2), and in non operated rabbit
(n=2).  Duplicate  measurements  were  obtained  from  all
samples.  Serial  dilutions  of  recombinant  human  VEGF-A
were included in all assays as a standard.
RESULTS
In vitro quantification of HC Ad.VEGF-A165: ARPE-19 cells
transduced with HC Ad.VEGF-A165 produced large amounts
of VEGF-A165. ELISA was performed nine days after the
transduction of the ARPE-19 cells, and the concentration of
VEGF-A165 was 162±15 ng/ml. No secretion of VEGF-A165
was obtained in the nontransduced ARPE-19 cells.
Biologic activity of HC Ad.VEGF-A165: To test the biologic
activity  of  VEGF-A165  produced  by  HC  Ad.VEGF-A165
transduced ARPE-19 cells at a MOI of 20, we performed
HUVEC  proliferation  and  migration  assays.  For  the
proliferation test, the supernatants from transduced ARPE-19
cells were added to the HUVEC cells in increasing dilutions.
Three days later, the relative proliferation of HUVEC cells in
the presence or absence of VEGF-A165 was determined. The
HUVEC  cells  proliferated  in  a  VEGF-A  concentration-
dependent  manner  compared  to  the  controls  (blind  and
medium  without  VEGF  and  bFGF).  However,  at  a  1:100
dilution (1.6 ng/ml), the ARPE-19 cells transduced with HC
Ad.VEGF-A did not produce sufficient VEGF-A to still exert
a proliferative effect (Figure 1A). As shown in Figure 1B,
unstimulated HUVEC cells (control: medium without VEGF
and  bFGF  in  the  lower  chambers)  exhibited  minimal
migration: after 6 h, only 100±5 cells per field had migrated
to  the  undersurface  of  the  filters.  In  contrast,  when
supernatants (162 ng/ml VEGF-A) from transduced ARPE-19
cells or a commercial VEGF-A (50 ng/ml) were added to the
lower  chambers,  extensive  and  VEGF-A  concentration-
dependent HUVEC cells migration was observed (749±19
cells versus 228±12 cells per field).
In vivo quantification of HC Ad.VEGF-A165: To estimate at
which levels human VEGF-A is produced in vivo during the
time of the follow-up examinations, an ELISA testing the
amount of human VEGF-A in the vitreous was performed. In
control eyes (not injected or after injection of HC Ad. EGFP),
human  VEGF-A  could  not  be  detected.  In  all  VEGF-A
transduced eyes, human VEGF-A was present in a stable
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1364Figure 6. Immunohistochemical findings after transduction with HC Ad.VEGF-A with hematoxylin and eosin counterstain. A: Staining with
tomato lectin showed that most cells penetrating the disrupted retinal pigment epithelium (RPE) cell layer were of endothelial origin (red).
Inner and outer retinal nuclear layers were mixed. Single RPE cells (black arrow) were surrounded by proliferating endothelial cells. B: VEGF-
A was highly expressed in the retinal scar (white asterisk) and in the RPE close to the retinal scar (black asterisk) but this expression rapidly
decreased the farther it was from the retinal scar (E). The expression of bFGF was not as strong in cells of choroidal origin than in retinal cells
(C). D: Proliferating cells at the retinal choroidal interface were immunoreactive for Ki67 (black arrowheads). The inset in (D) demonstrates
the endothelial nature of dividing cells by double labeling for Ki67 (red) and tomato lectin (green). F: Albumin (red) was present in the choroid
and the fiber matrix at the vitreoretinal interface. It was absent in the unaffected retina (black asterisk). Two selected areas are shown enlarged
(G, H). Choroidal retinal scarring and leakage of albumin are visible in one of the enlarged areas (G). Albumin was not localized within
proliferating cells surrounding single RPE cells (black arrows). This may be why ICG did not enter such sites (see Figure 2I,M). H: The
second enlarged area revealed albumin leakage within the retina that, as shown in this panel, was not fused with RPE or choroid (Ch).
Abbreviations: INL, inner nuclear layer; GCL, ganglion cell layer.
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1365concentration in the vitreous (67±12 pg/ml and 40±10 pg/ml,
respectively) two and four weeks after the gene transfer.
Fluorescence  angiography  in  scanning  laser
ophthalmoscopy: After transduction with HC Ad.FK7, RPE
cells expressed green fluorescent protein (Figure 2A). FA
(Figure 2B) or ICG (Figure 2C) did not show blood vessel
leakage or abnormalities in any of the four eyes (Table 1). The
same was true for the areas in which PBS had been injected
subretinally in both eyes (Table 1). No alterations were found
after ICG. After transduction with Ad. Empty (Figure 2D,E),
which is known to be toxic to the RPE [24], FA (Figure 2D)
and ICG (Figure 2E) showed the same image representing a
typical window effect. Two weeks (Figure 2F-I) and four
weeks (Figure 2J-M) after transduction with HC Ad.VEGF-
A, FA and ICG angiographies were similar. However, after
transduction with 5x106 iu HC Ad.VEGF-A, FA showed that
the areas of injection were hyperfluorescent in 15 out of 18
eyes. These hyperfluorescent areas were either spotty (Figure
2F,H,J,L)  or  laminary  (not  shown).  Moreover,  the
quantification of fluorescence intensity at the lesion site after
FA revealed that four weeks postinjection, the Δlight intensity was
on average six times higher in eyes that were injected with HC
Ad. VEGF-A compared to the eyes that were injected with
HC  Ad.FK7  (Figure  3).  Early  ICG  revealed  irregularities
close to the deeper choroidal blood vessels (arrow in Figure
2G,K).  Late  ICG  angiography  (Figure  2I,M)  stained  the
environment of spotty roundish areas shown in (Figure 2H,L).
Within the interstitium around cellular proliferations as shown
in Figure 4.
Light  microscopy  of  plastic  sections:  The  following
observations were made in all nine eyes investigated at the
electron  microscopic  level  and  had  been  injected  with
5x106 iu HC Ad.VEGF-A (Table 1). Below the transduced
RPE layer, the endothelial cells of the choriocapillaris were
irregular, and endothelial cells protruded into the vessel lumen
(Figure  4).  Evidence  for  this  is  presented  by  electron
microscopy (see also Figure 5A-C). The RPE cell layer was
frequently  disrupted,  and  endothelial  cells  migrated  and
proliferated  into  the  subretinal  space  or  between  Bruch’s
membrane and the RPE (Figure 4A, inset). Evidence that these
cells  were  endothelial  cells  was  demonstrated  by
immunohistochemistry (see Figure 6A). Cellular proliferation
within the subretinal space was either solid (white asterisk in
Figure 4A) or loosely packed with interstitial spaces (black
asterisk in Figure 4B). The nuclei of the photoreceptors were
mixed with the nuclei of the inner nuclear layer, and a retinal
scar was closely connected to the RPE and proliferating cells.
This was probably the reason why fluorescein leakage was
restricted  to  the  spotty  round  areas  seen  in  Figure  2D,F.
Immature  capillaries  containing  erythrocytes  were  located
distally to the RPE (white arrow in Figure 4B) or in the
subretinal  space  (Figure  7,  insert).  The  thickness  of  the
extracellular matrix and vessel layers of the choroid was three
to four times enlarged after transduction with VEGF vector
compared to the controls (double arrows in Figure 4A,B).
After injection of PBS (in two eyes) or 5x106 iu HC Ad. FK7
(in four eyes), the RPE, the choriocapillaris (arrowheads), and
deeper choroidal vessels (arrow), as well as the pigmented
layer  consisting  predominately  of  melanocytes,  appeared
normal (Figure 4C,D).
Immunohistochemistry: After HC Ad.VEGF-A transduction,
staining of endothelial cells with tomato lectin showed that
most cells penetrating the disrupted RPE cell layer were of
endothelial origin. Proliferating endothelial cells surrounded
single RPE cells in the subretinal space (Figure 6A). After
Figure  7.  Newly  formed  capillary  in  the  subretinal  space  after
transduction with HC Ad.VEGF-A from the same eye as shown in
Figures 2J,K. The inset (left bottom) shows a semithin section with
a new capillary (black arrowhead) within the subretinal space and
erythrocytes originating probably from subretinal bleeding (white
arrowhead). The photoreceptors of the retina have degenerated and
were  no  longer  visible.  Electron  microscopy  revealed  the  same
capillary close to the level of the semithin section. The endothelium
was very thin, lacking extracellular matrix. However, it contained
vacuoles  (asterisks).  The  endothelium  did  not  contain  any
fenestrations, and the lumen was free of erythrocytes (E). Note the
extremely  frayed  or  fragmented  nucleus  of  an  endothelial  cell
(arrow). The nucleus (N) of the endothelial cell that formed the vessel
tube appeared normal. The RPE formed two layers (bottom right).
Molecular Vision 2008; 14:1358-1372 <http://www.molvis.org/molvis/v14/a164> © 2008 Molecular Vision
1366Molecular Vision 2008; 14:1358-1372 <http://www.molvis.org/molvis/v14/a164> © 2008 Molecular Vision
1367
T
A
B
L
E
 
2
.
 
D
I
F
F
E
R
E
N
T
 
M
E
T
H
O
D
S
 
U
S
E
D
 
T
O
 
I
N
D
U
C
E
 
C
N
V
 
I
N
 
R
A
B
B
I
T
S
M
e
t
h
o
d
s
F
l
u
o
r
e
s
c
e
i
n
 
a
n
g
i
o
g
r
a
p
h
y
C
h
o
r
o
i
d
a
l
 
n
e
o
v
a
s
c
u
l
a
r
i
z
a
t
i
o
n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F
e
n
e
s
t
r
a
t
i
o
n
s
 
o
f
 
n
e
w
l
y
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(
C
N
V
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
f
o
r
m
e
d
 
v
e
s
s
e
l
s
 
d
e
t
e
c
t
e
d
b
y
 
E
M
R
P
E
I
n
f
l
a
m
m
a
t
i
o
n
R
e
f
e
r
e
n
c
e
S
u
b
r
e
t
i
n
a
l
 
i
n
j
e
c
t
i
o
n
 
o
f
 
v
i
t
r
e
o
u
s
N
e
g
a
t
i
v
e
,
 
n
o
 
l
e
a
k
a
g
e
S
u
b
r
e
t
i
n
a
l
 
v
e
s
s
e
l
s
 
i
n
 
3
3
%
–
5
5
%
 
o
f
t
h
e
 
e
y
e
s
a
f
t
e
r
 
4
–
4
0
 
w
e
e
k
s
N
o
r
m
a
l
 
f
e
n
e
s
t
r
a
t
i
o
n
M
i
g
r
a
t
i
o
n
;
 
p
r
o
l
i
f
e
r
a
t
i
o
n
n
.
d
.
[
3
4
]
R
e
t
i
n
o
t
o
m
y
 
w
i
t
h
 
a
r
g
o
n
 
l
a
s
e
r
b
u
r
n
s
N
o
t
 
c
l
i
n
i
c
a
l
l
y
 
a
p
p
a
r
e
n
t
 
s
u
b
r
e
t
i
n
a
l
n
e
o
v
a
s
c
u
l
a
r
i
z
a
t
i
o
n
M
i
c
r
o
s
c
o
p
i
c
a
l
s
u
b
r
e
t
i
n
a
l
 
n
e
o
v
a
s
c
u
l
a
r
i
z
a
t
i
o
n
N
o
r
m
a
l
 
f
e
n
e
s
t
r
a
t
i
o
n
D
i
s
r
u
p
t
i
o
n
M
a
c
r
o
p
h
a
g
e
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[
3
3
]
V
E
G
F
 
p
e
l
l
e
t
s
 
i
n
t
o
 
t
h
e
 
v
i
t
r
e
o
u
s
L
e
a
k
a
g
e
 
i
n
 
r
e
t
i
n
a
l
 
v
e
s
s
e
l
s
 
b
e
t
w
e
e
n
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7
 
a
n
d
1
4
 
d
a
y
s
n
.
d
.
n
.
r
.
;
e
l
e
c
t
r
o
n
 
m
i
c
r
o
g
r
a
p
h
s
 
o
f
 
i
m
m
a
t
u
r
e
v
e
s
s
e
l
s
 
d
o
n
o
t
 
s
h
o
w
 
f
e
n
e
t
r
a
t
i
o
n
s
n
.
d
.
n
.
r
.
[
2
5
]
S
u
b
r
e
t
i
n
a
l
 
i
n
j
e
c
t
i
o
n
 
o
f
 
b
F
G
F
m
i
c
r
o
p
h
e
r
e
s
n
.
d
.
N
e
o
v
a
s
c
u
l
a
r
 
c
h
a
n
n
e
l
s
 
u
p
 
t
o
 
8
 
w
e
e
k
s
n
.
d
.
M
i
g
r
a
t
i
o
n
;
 
p
r
o
l
i
f
e
r
a
t
i
o
n
M
a
c
r
o
p
h
a
g
e
s
 
a
p
p
e
a
r
e
d
e
a
r
l
y
 
b
u
t
 
t
h
e
n
 
d
i
s
a
p
p
e
a
r
e
d
[
3
0
,
3
9
]
S
u
b
r
e
t
i
n
a
l
 
i
m
p
l
a
n
t
a
t
i
o
n
 
o
f
m
i
c
r
o
s
h
e
r
e
s
 
i
m
p
r
e
g
n
a
t
e
d
 
 
 
 
 
 
 
 
 
 
 
 
4
 
w
e
e
k
s
w
i
t
h
F
G
F
C
N
V
 
l
e
a
k
a
g
e
 
i
n
 
t
h
e
 
e
y
e
s
 
a
f
e
r
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S
u
b
r
e
t
i
n
a
l
 
v
e
s
s
e
l
s
 
i
n
 
n
e
o
v
a
s
c
u
l
a
r
m
e
m
b
r
a
n
e
s
n
.
d
M
i
g
r
a
t
i
o
n
;
 
p
r
o
l
i
f
e
r
a
t
i
o
n
M
a
c
r
o
p
h
a
g
e
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[
4
0
]
S
u
b
r
e
t
i
n
a
l
 
i
n
j
e
c
t
i
o
n
 
o
f
 
l
i
p
i
d
e
h
y
d
r
o
p
e
r
o
x
i
d
e
A
f
t
e
r
 
1
0
0
 
µ
g
9
%
–
1
5
%
 
a
f
t
e
r
 
4
 
w
e
e
k
s
H
i
s
t
o
l
o
g
i
c
a
l
l
y
 
d
e
t
e
c
t
e
d
 
i
n
 
4
6
%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
o
r
m
a
l
 
f
e
n
e
s
t
r
a
t
i
o
n
o
f
 
t
h
e
 
e
y
e
s
D
e
t
a
c
h
m
e
n
t
,
 
d
a
m
a
g
e
M
a
c
r
o
p
h
a
g
e
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[
3
2
]
S
u
b
r
e
t
i
n
a
l
 
i
n
j
e
c
t
i
o
n
 
o
f
 
F
G
F
-
2
a
n
d
 
L
P
S
 
i
n
 
H
e
p
a
r
i
n
-
S
e
p
h
a
r
o
s
e
b
e
a
d
s
C
N
V
 
l
e
a
k
a
g
e
 
i
n
 
1
0
0
%
 
o
f
 
t
h
e
 
e
y
e
s
a
f
e
r
 
2
w
e
e
k
s
 
a
n
d
 
3
 
m
o
n
t
h
s
C
N
V
 
i
n
 
a
l
l
 
i
n
j
e
c
t
i
e
d
 
e
y
e
s
n
.
d
P
r
o
l
i
f
e
r
a
t
i
o
n
R
e
l
a
t
i
o
n
s
h
i
p
 
o
f
M
a
k
r
o
p
h
a
g
e
s
 
t
o
 
C
N
V
[
2
9
]
S
u
b
r
e
t
i
n
a
l
 
i
n
j
e
c
t
i
o
n
 
o
f
 
m
a
t
r
i
g
e
l
a
l
o
n
e
 
o
r
 
i
n
 
c
o
m
b
i
n
a
t
i
o
n
 
w
i
t
h
V
E
G
F
C
N
V
 
l
e
a
k
a
g
e
 
i
n
 
1
0
0
%
 
o
f
 
t
h
e
 
e
y
e
s
a
f
e
r
 
2
-
4
 
w
e
e
k
s
 
a
l
s
o
 
w
i
t
h
o
u
t
 
V
E
G
F
C
N
V
 
i
n
 
1
0
0
%
 
o
f
 
t
h
e
 
e
y
e
s
 
a
f
e
r
2
 
-
 
4
 
w
e
e
k
s
a
l
s
o
 
w
i
t
h
o
u
t
 
V
E
G
F
n
.
d
.
D
i
s
p
l
a
c
e
m
e
n
t
,
v
a
c
u
o
l
i
s
a
t
i
o
n
,
d
e
p
i
g
m
e
n
t
a
t
i
o
n
M
a
n
y
 
i
n
f
l
a
m
m
a
t
o
r
y
 
c
e
l
l
s
 
 
 
 
 
 
 
[
2
6
]
I
n
j
e
c
t
i
o
n
 
o
f
 
A
d
V
E
G
F
-
A
 
i
n
t
o
t
h
e
v
i
t
r
e
o
u
s
n
.
d
.
n
.
r
.
n
.
d
.
n
.
r
.
S
t
r
o
n
g
 
i
n
f
l
a
m
m
a
t
o
r
y
r
e
a
c
t
i
o
n
[
2
7
]
S
u
b
r
e
t
i
n
a
l
 
i
n
j
e
c
t
i
o
n
 
o
f
 
H
C
-
A
d
V
E
G
F
-
A
C
N
V
 
l
e
a
k
a
g
e
 
i
n
 
8
3
%
 
o
f
 
t
h
e
 
e
y
e
s
a
f
t
e
r
 
2
–
4
 
w
e
e
k
s
 
(
5
x
1
0
6
 
i
.
u
.
)
O
b
s
e
r
v
e
d
 
a
f
t
e
r
 
2
–
4
 
w
e
e
k
s
N
o
t
 
f
o
u
n
d
 
i
n
 
n
e
w
l
y
 
f
o
r
m
e
d
 
v
e
s
s
e
l
s
M
i
g
r
a
t
i
o
n
;
 
p
r
o
l
i
f
e
r
a
t
i
o
n
F
e
w
 
m
a
c
r
o
p
h
a
g
e
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
r
e
s
e
n
t
 
s
t
u
d
y
T
h
i
s
 
t
a
b
l
e
 
s
u
m
m
a
r
i
z
e
s
 
t
h
e
 
d
a
t
a
 
f
r
o
m
 
t
h
e
 
l
i
t
e
r
a
t
u
r
e
 
c
o
n
c
e
r
n
i
n
g
 
t
h
e
 
d
i
f
f
e
r
e
n
t
 
m
e
t
h
o
d
s
 
o
f
 
C
N
V
 
i
n
d
u
c
t
i
o
n
 
i
n
 
r
a
b
b
i
t
s
.
 
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
n
.
d
.
=
n
o
t
 
d
e
t
e
r
m
i
n
e
d
,
 
n
.
r
.
=
n
o
t
r
e
p
o
r
t
e
d
.injection of PBS, only the veins of the retina or the vessels of
the choroid with a clear straight borderline to the RPE were
stained (not shown).
VEGF-A was highly expressed in transduced RPE cells
(Figure 6E). VEGF-A was also strongly expressed in areas
with retinal thickening and mixing of inner and outer nuclear
layers (Figure 6B). After injection of PBS in the retina, only
the  inner  segments  of  the  photoreceptors  and  retinal  or
choroidal vessels showed VEGF immunoreactivity, whereas
the RPE was not positive (not shown). bFGF was highly
expressed in the scarring retina, particularly in Mueller glial
cells and in cells of unknown origin at the interface between
retina and choroid. bFGF immunoreactivity was lower in cells
of choroidal origin than in retinal cells (Figure 6C). After
injection of PBS, only the Mueller cells, the RPE and cells in
the choroid showed bFGF immunoreactivity (not shown).
At  sites  where  HC  Ad.VEGF-A  had  been  injected,
division of cells in the choroid was regularly detected by Ki67
immunoreactivity. Double labeling for Ki67 and tomato lectin
indicated the endothelial nature of some of the dividing cells
(Figure 6D). After injection of PBS, only a few cells were
positive for Ki67 (about 1–2 cells per whole choroid of an eye,
not shown).
Albumin immunoreactivity was present in the choroid
and the fiber matrix at the vitreal retinal interface. It was
absent in the unaffected retina (Figure 6F). In retina close to
the  choroidal  endothelial  cell  proliferation,  albumin  was
detected within the retina. Albumin immunoreactivity was not
localized within the nodular cell cluster surrounding the RPE
cells (Figure 6G). This may be why ICG did not enter such
sites (see Figure 2G). Albumin leakage within the retina also
occurred at sites where the retina was not fused with the RPE
or choroid (Figure 6H). After injection of PBS, only choroid
and  vitreous,  but  not  the  retina,  stained  for  albumin  (not
shown). Single macrophages were regularly detected with
CD68 antigen at the injection sites (not shown).
Electron  microscopy:  After  HC  Ad.VEGF  transduction,
nuclei of the choriocapillaris appeared extremely frayed or
fragmented  (Figure  8A).  Thrombocytes  aggregated  in  the
choriocapillaris, and cells migrated into Bruch’s membrane
between the RPE and choriocapillaris. The adherent junctions
were opened, and the extracellular matrix then had direct
contact  with  the  lumen  of  the  capillary  (Figure  8B,C).
Choriocapillaries  were  frequently  completely  closed  by
thrombi. Below the transduced RPE layer, the endothelial
cells of the choriocapillaris were irregular and endothelial
cells protruded into the vessel lumen as shown in Figure 4.
Electron microscopy revealed that this was often caused by
invaginations of the endothelium toward the vessel lumen.
These  invaginations  were  filled  with  high  amounts  of
extracellular matrix (Figure 5A). Whole cells, surrounded by
extracellular matrix, were located between the endothelium
and Bruch’s membrane (Figure 5B). Endothelial cells formed
fingerlike protrusions through the elastic layer into Bruch’s
membrane (Figure 5C). Sites indicating remodeling and de
novo synthesis of the extracellular matrix surrounding the
choriocapillaris were always present (Figure 5C). Whole cells
were regularly present within Bruch’s membrane (Figure 5D).
Newly formed capillaries were detected within the subretinal
space (Figure 7). Subretinal bleedings were also present. The
endothelium of such capillaries was unusually thin, lacking
extracellular  matrix  but  containing  vacuoles.  The
endothelium of such newly formed vessels did not contain any
fenestrations, and the lumen was often free of erythrocytes.
DISCUSSION
Different approaches have been undertaken to induce CNV in
rabbits  (Table  2),  and  VEGF  was  used  to  induce
neovascularization in only three reports [25-27]. However, in
just one of these studies, CNV was successfully induced but
VEGF was not the principal inducer of neovascularization
Figure 8. Electron micrographs obtained after transduction with
HC  Ad.VEGF-A.  A:  Nuclei  of  the  choriocapillaris  appeared
extremely frayed or fragmented (asterisks). Remnants of the elastic
layer  of  Bruch’s  membrane  can  be  recognized  (arrows).  B:
Trombocytes (T) aggregated in the choriocapillaris. Cells (black
asterisk)  migrated  into  Bruch’s  membrane  between  RPE  and
choriocapillaris.  The  elastic  layer  is  marked  by  an  arrow.  C:
Magnification of the frame in (B) showed that the adherent junctions
were opened and the extracellular matrix had direct contact with the
lumen  of  the  capillary  (arrow).  D:  The  choriocapillaris  was
completely closed by thrombi (T), which was directly faced Bruch’s
membrane (B). The endothelium (E) was thickened and interrupted
by another cell (black asterisk). Scale bars in each image equal 1
μm.
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1368because matrigel alone had the same effect as matrigel in
combination with VEGF [26]. Therefore, the purpose of our
study was to develop an efficient and reliable model of CNV
to facilitate the study of antiangiogenic and antiproliferative
therapies for ocular diseases. This is currently the only model
that shows an induction of CNV by overexpression of VEGF
in the rabbit. In the present investigation, we observed a CNV
with leakage four weeks after the subretinal injection of HC
Ad.VEGF-A  at  5x106  iu  in  83%  of  the  rabbit  eyes.  This
observed  leakage  did  not  look  like  the  diffuse  leakage
observed by patients probably because it was just restricted to
the area in which there was an overexpression of VEGF-A–
i.e., close to the retinal scar as shown in Figure 6B,E. A
window effect as shown in Figure 2D,E was excluded since
the RPE was present and the choroidal vessels could not be
seen after FA (Figure 2J,L,F,H). We also combined several
detection  methods  of  VEGF-A165  overexpression  induced
neovascularization  in  mammals  (SLO,  angiography,  light
microscopy, and electron microscopy). Our findings present
clear  indications  that  there  is  a  significant  effect  on  the
endothelial  cells  of  the  choriocapillaris  after  a  subretinal
transduction of the RPE with VEGF-A vector. Moreover, we
have described damage of preexisting choriocapillaris and
remodeling of extracellular matrix. In accordance with most
of the existing rabbit models, we also observed alterations in
RPE cells and activation of macrophages that were absent
after EGFP transduction (Table 2). The choroidal endothelial
cells  were  activated,  adherent  junctions  opened  creating
thrombosis  and  leakage.  The  fenestration  was  minimised,
while the endothelial cells augment the extracellular matrix
and  they  begin  to  migrate  and  infiltrate  the  Bruch’s
membrane. Moreover, they proliferate and form pathological
vessels in the subretinal space. We also observed an increased
expression  of  bFGF  and  VEGF-A  accompanied  by
macrophage stimulation, retinal edema, and photoreceptor
loss.  In  our  model,  upregulation  of  VEGF  induced  a
pathological mechanism, in which the choriocapillaris was
closed  by  thrombocyte  aggregation,  probably  inducing
hypoxia. Then, hypoxia induced autoregulatory pathways that
may have increased or decreased growth factors like bFGF
(Figure  6C).  This  cascade  altered  the  microenvironment
leading  to  CNV.  The  fact  that  in  laser  models,  VEGF  is
secreted or that expression of VEGF induces CNV in specific
models does not demonstrate that VEGF plays a major role in
the  development  of  CNV  in  humans  with  AMD.  The
conclusions  we  refer  to  are  that,  in  normal  animal  eyes,
overexpression of VEGF can induce remodeling of retinal and
choroidal  vessels  and  that  many  of  the  features  of  our
experimental CNV are similar to those observed clinically in
patients  having  wet  AMD  (Table  3).  Once  the  CNV  is
established, it can last for years. Complications, such as retinal
and  choroidal  atrophy,  retinal  detachment,  and  RPE  cell
dysfunction can finally lead to blindness [28]. Indeed, in a
previous study by Ni et al. [29], the authors described the time
course of experimental CNV induced in rabbits by subretinal
injection of endotoxin and bFGF encapsulated into a sustained
release format (heparin-sepharose). They demonstrated that
the presence of macrophages and the activation of the RPE
cells in association with development of CNV suggested an
inflammatory component, together with remodeling process,
as a major contributor to the development of their model of
CNV. They also showed a persistence of clinically leaky CNV
lesions  throughout  the  three-year-observation  period
following a single dose of angiogenic molecules. In most
cases, the peak time of CNV leakage appeared at week four
[26]. In contrast, laser-induced CNV in rodents and primates
has been reported to last usually for just one month. With
laser-induced CNV, the peak fluorescein leakage appeared at
week two and then gradually resolved because of the rapid
maturation of new blood vessels and the reestablishment of
the blood-retinal barrier [9]. This is why we chose two and
four weeks as time points for our investigations. We did not
observe  important  differences  when  comparing  the
angiographies at weeks two or four postoperative indicating
that the weak leakage observed at week four was not due to
fibrosis and regressing vessels.
The current study is the first in which a direct effect on
the choroidal endothelial cells after transduction with a VEGF
vector in rabbits has been proven. Although Matrigel was
subretinally injected in combination with VEGF in an earlier
study [26], the VEGF had no effect there, and the subretinal
injection of Matrigel alone showed the same effect on the
choroidal blood vessels. In this study, introducing gel-like
Matrigel  compounds  into  the  subretinal  space  created  a
physical barrier between the neural retina and its underlying
choroid tissues. Therefore, the mechanism leading to CNV
seems  to  be  different  from  AMD,  where  basal  laminar
deposits are located in Bruch’s membrane between RPE and
choroid.
In a 2006 study done by Kinnunen et al. [27], a VEGF-A
adenovirus was injected into the vitreous body. Production of
VEGF, endothelial cell proliferation, as well as increased
capillary density in the retina, the optic nerve head, and the
anterior segments were also detected. However, the effect on
the choroidal vessels was not investigated.
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TABLE 3. SIMILITUDE OF   OUR   EXPERIMENTAL   RABBIT CNV MODELWITH
THE FEATURES
 
OBSERVED
 
IN PATIENTS   SUFFERING   FROM   WET AMD.
-> Changes in the RPE (hypo- or hyperpigmentation)
-> Bruch’s membrane loss and infiltration of endothelial cells
-> Remodelling of extracellular matrix
-> Subretinal neovascularisation
-> Proliferation of endothelial cells and fibroblasts
-> Subretinal haemorrhage
-> Leakages
-> Thrombosis
-> Loss of photoreceptors
-> Retinal edema
-> Upregulation of bFGF and VEGFOther  investigators  have  reported  using  angiogenic
molecules to induce CNV in rabbits [25,30-34]. Tamai et al.
[32] reported fluorescein leakage after four weeks in 9%–15%
of rabbit eyes using subretinal injection of lipid hydroperoxide
(100 μg), whereas CNV formation was found in up to 46% of
rabbit  eyes.  They  also  performed  light  and  transmission
electron microscopy, which showed a degeneration of the
retina accompanied by a detachment of RPE, and the presence
of macrophages. They also described a normal fenestration of
newly  formed  vessels  detected  by  electron  microscopy.
Investigators  also  attempted  to  stimulate  CNV  in  rabbits
through intravitreal VEGF administration [25]; however, only
a  transient  (three  weeks)  retinal  neovascularization  was
observed  following  intravitreous  implantation  of  VEGF
pellets. In a 1991 study [33], the authors tried to create CNV
by performing retinotomy with argon laser burns. Although
they did not observe clinically apparent CNV, all laser lesions
contained microscopic CNV. This model was also associated
with a degeneration of the retina, the disruption of RPE, and
the presence of macrophages. The first described model of
experimental subretinal neovascularization in the rabbit was
performed in 1989 and was induced by subretinal injection of
vitreous  without  rupture  of  Bruch’s  membrane  [34].  The
incidence of CNV rose from 33% to 57% in a period of 4–40
weeks.  Because  of  the  absence  of  any  fluorescein
angiographic indication of CNV, these occult new vessels
were identified by light and transmission electron microscopy.
Histological examination showed that these newly formed
vessels were composed of continuous capillaries and had the
morphologic  characteristics  of  choriocapillaris,  including
fenestrations,  basement  membranes,  and  junctional
complexes.  The  new  vessels  originated  from  the
choriocapillaris and penetrated through Bruch’s membrane
into the subretinal space, where they were associated with the
degenerated retina and proliferating glial and/or RPE cells.
To  conclude,  our  rabbit  model  for  CNV  offers  the
possibility to define not only the molecular signals involved
but also to examine how they interact and how the specific
microenvironments in the eye influence neovascularization.
It will also provide additional new targets for intervention and
allow testing of drugs that block the targets. Inhibitors of
VEGF signaling have already been demonstrated to be useful
for prevention of retinal neovascularization or CNV in animal
models and in patients [35-38]. A major goal for the future is
to  precisely  identify  and  test  precisely  new  agents  or
combination  of  agents  that  cause  regression  of
neovascularization in a rabbit model like ours under exactly
defined conditions.
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